Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Atenolol; Hydrochlorothiazide
- Indications Hypertension
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Acronyms PEAR; PEAR-1
- 31 Oct 2013 Status of the extension study changed from "active, no longer recruiting" to "completed" as reported by the ClinicalTrials.gov record. Actual patient number is 44.
- 31 Oct 2013 Status of the extension study changed from "active, no longer recruiting" to "completed" as reported by the ClinicalTrials.gov record. Actual patient number is 44.
- 31 Oct 2013 Status of the extension study changed from "active, no longer recruiting" to "completed" as reported by the ClinicalTrials.gov record. Actual patient number is 44.